BindingDB logo
myBDB logout

20 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
26258602 39 Discovery of Selective Small Molecule Inhibitors of Monoacylglycerol Acyltransferase 3.EBI Pfizer Inc.
26218650 41 Discovery and optimization of adamantane carboxylic acid derivatives as potent diacylglycerol acyltransferase 1 inhibitors for the potential treatment of obesity and diabetes.EBI Korea Research Institute of Chemical Technology
25897973 29 Discovery of a Novel Series of N-Phenylindoline-5-sulfonamide Derivatives as Potent, Selective, and Orally Bioavailable Acyl CoA:Monoacylglycerol Acyltransferase-2 Inhibitors.EBI Takeda Pharmaceutical Co., Ltd.
24900877 107 Development of novel benzomorpholine class of diacylglycerol acyltransferase I inhibitors.EBI Merck Research Laboratories
24618302 49 Discovery of novel quinoline carboxylic acid series as DGAT1 inhibitors.EBI Merck Research Laboratories
24670009 65 Discovery of 6-phenylpyrimido[4,5-b][1,4]oxazines as potent and selective acyl CoA:diacylglycerol acyltransferase 1 (DGAT1) inhibitors with in vivo efficacy in rodents.EBI Amgen Inc.
23871442 88 Defining the key pharmacophore elements of PF-04620110: discovery of a potent, orally-active, neutral DGAT-1 inhibitor.EBI Pfizer Inc.
23810496 31 Synthesis and biological evaluation of aminobenzimidazole derivatives with a phenylcyclohexyl acetic acid group as anti-obesity and anti-diabetic agents.EBI Korea Research Institute of Chemical Technology
23541669 92 Identification and design of a novel series of MGAT2 inhibitors.EBI AstraZeneca
23317570 42 Lead optimization of a pyridine-carboxamide series as DGAT-1 inhibitors.EBI Merck Research Laboratories
23116186 68 Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687).EBI AstraZeneca
22263872 15 Identification and preliminary characterization of a potent, safe, and orally efficacious inhibitor of acyl-CoA:diacylglycerol acyltransferase 1.EBI Abbott Laboratories
24900485 13 Intestinally Targeted Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitors Robustly Suppress Postprandial Triglycerides.EBI TBA
24900321 10 Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1.EBI TBA
22217874 49 Design and synthesis of potent carboxylic acid DGAT1 inhibitors with high cell permeability.EBI Prosidion Ltd
21413799 63 Discovery of orally active carboxylic acid derivatives of 2-phenyl-5-trifluoromethyloxazole-4-carboxamide as potent diacylglycerol acyltransferase-1 inhibitors for the potential treatment of obesity and diabetes.EBI Hoffmann-La Roche Inc.
19256504 18 Discovery of a potent, selective, and orally efficacious pyrimidinooxazinyl bicyclooctaneacetic acid diacylglycerol acyltransferase-1 inhibitor.BDB AstraZeneca